Kiniksa Pharmaceuticals International (KNSA) reported a Q4 loss Tuesday of $0.12 per diluted share, swinging from earnings of $0.35 per share a year earlier.
Analysts polled by FactSet expected earnings of $0.02.
Revenue for the quarter ended Dec. 31 was $122.5 million, up from $83.4 million a year earlier.
Analysts surveyed by FactSet expected $123.4 million.
Shares of the biotech firm were down more than 6% in recent premarket activity.
Price: 18.28, Change: -1.35, Percent Change: -6.89
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。